Lilly Endowment Inc., a major shareholder in Eli Lilly, sold 301,342 shares of the company's stock for a total value of approximately $260.16 million. The transactions, which took place on October 31, 2025, were reported in a regulatory filing on November 3, 2025. The sales occurred at weighted average prices between $862.00 and $869.91 per share. Following the sale, the Lilly Endowment still directly owns over 94.2 million shares of the company. The news of the insider sale comes as Eli Lilly continues to pursue advancements in its clinical pipeline, with ongoing studies for treatments in smoking cessation, diabetes, and oncology. No market analysis on the impact of this specific sale was available.